ArachidonoylEthanolamidePhosphate , 98% , 183323-26-4

CAS NO.：183323-26-4

Empirical Formula: C22H38NO5P

Molecular Weight: 427.51

MDL number: MFCD08062225

PRODUCT Properties

• Density: 1.075±0.06 g/cm3(Predicted)
• solubility: DMF: 20 mg/ml; DMSO: 20 mg/ml; Ethanol: 30 mg/ml; PBS (pH 7.2): 5 mg/ml
• pka: 1.86±0.10(Predicted)

Description and Uses

Arachidonoyl ethanolamide (AEA; ) was the first endogenous cannabinoid (CB) to be isolated and characterized as an agonist acting on the same receptors (CB₁ and CB₂) as Δ⁹-THC . Since that time, a number of related endocannabinoids have been isolated, most notably 2-arachidonoyl glycerol (2-AG; ). The phosphate ester of AEA, AEA-P, has been tested as a water soluble prodrug version of AEA in the treatment of C₆ glioma cells in vivo. Here it acts with essentially the same potency as AEA. However, when tested for inhibition of AEA binding to isolated rat brain CB₁ receptors, AEA-P is about 5-fold less potent as an agonist with a K_i of about 200 nM. The phosphate esters of AEA and its analogs are also structural variants of lysophosphatidic acid (LPA). However, the effects of AEA-P on the various LPA receptors have not been tested.

Arachidonoyl ethanolamide phosphate, an endocannabinoid, is an endogenous ligand for cannabinoid receptors in the central nervous system (CB1 subtype) and peripheral immune cells (CB2 subtype)[1][2].

Safety

• Symbol(GHS): GHS02
• Signal word: Danger
• Hazard statements: H225
• Precautionary statements: P210-P233-P240-P241-P242-P243-P280-P303+P361+P353-P370+P378-P403+P235-P501